长春金赛药业,金培生长激素注射液新增规格获批(162 iu/27 mg、324 iu/54 mg,国药准字 S20269020、S20269021),2026-10
中华医学会儿科学分会内分泌遗传代谢学组.《中国儿童生长激素缺乏症诊治指南(2024)》
国家医疗保障局,2025 年国家医保药品目录(长效生长激素首次纳入,2026-01-01 落地)
Grimberg A, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016;86:361-397. DOI: 10.1159/000452150
Growth Hormone Research Society. 2026 Consensus Statement(首次系统性纳入中国大样本循证证据)
Allen DB, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1-P9. DOI: 10.1530/EJE-15-0873
Carel JC, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416-425. DOI: 10.1210/jc.2011-1995